Acute myeloid leukaemia
Not recruitingStudy of liposomal annamycin and cytarabine combination for patients with acute myeloid leukemia (AML) who are newly diagnosed or have not responded to previous treatment
Study of liposomal annamycin and cytarabine combination for patients with acute myeloid leukemia (AML) who are newly diagnosed or have not responded to previous treatment
- Disease:Acute myeloid leukaemia
- Substances:AnnamycinCytarabine
Poland- Participants:18–64 years · 65+ years
- Substances:Annamycin
- Sponsor:Moleculin Biotech Inc.












